Efficacy of Zonisamide in the treatment of children with refractory epilepsy
Not Applicable
- Conditions
- interactable epilepsy.Episodic and paroxysmal disorders
- Registration Number
- IRCT2012091210508N2
- Lead Sponsor
- Shahid Beheshti University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 67
Inclusion Criteria
children one to eighteen years, having resistant epilepsy; referred to Mofid Children's Hospital
Exclusion criteria: children with neurodegenerative diseases
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Seizure. Timepoint: 1 and 6 months after drug starting. Method of measurement: Interview.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Zonisamide's efficacy in refractory epilepsy with paroxysmal disorders?
How does Zonisamide compare to levetiracetam or valproate in pediatric refractory epilepsy treatment outcomes?
Which genetic biomarkers (e.g., SCN1A, KCNQ2) predict Zonisamide response in IRCT2012091210508N2 trial participants?
What are the safety profiles and management strategies for Zonisamide-induced sedation in Mofid Hospital pediatric trials?
What combination therapies with Zonisamide (e.g., lamotrigine, topiramate) show synergistic effects in refractory epilepsy management?